Adalimumab and Antibodies to Adalimumab Quantitation
Also known as: ADA PAN
Use
This test is used to monitor adalimumab or adalimumab biosimilar therapy in patients. It quantifies the concentration of adalimumab and detects antibodies that may develop against the drug, providing information on the therapeutic effectiveness and the potential development of drug resistance due to immune response. Results are interpreted in the context of adalimumab trough concentrations to determine clinical significance and impact on treatment efficacy.
Special Instructions
Not provided.
Limitations
The limit of quantitation for adalimumab is 0.4 ug/mL and for antibodies to adalimumab is 20 ng/mL. While therapeutic levels may vary depending on the disease treated, results below these limits may not accurately reflect the presence of the drug or antibodies. Gross hemolysis, icterus, or lipemia in specimens can lead to rejection. Repeated freeze/thaw cycles should be avoided.
New York Approved
Methodology
Immunoassay (ECLIA)
Biomarkers
LOINC Codes
- 86894-3 - Adalimumab SerPl IA-mCnc
- 86895-0 - Adalimumab Ab SerPl IA-mCnc
Result Turnaround Time
3-7 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.1 mL
Container
Serum separator tube
Collection Instructions
Collect specimens before next scheduled dose of adalimumab or adalimumab biosimilar. Avoid exposure to biotin (vitamin B7) for 12 hours prior to specimen collection.
Patient Preparation
Avoid exposure to biotin (vitamin B7) for 12 hours prior to specimen collection.
Causes for Rejection
Grossly hemolyzed, icteric, or lipemic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 2 days |
| Refrigerated | 2 weeks |
| Frozen | 1 month; avoid repeated freeze/thaw cycles. |
Other tests from different labs that may be relevant